Literature DB >> 30784705

Anticancer properties of a new non-oxido vanadium(IV) complex with a catechol-modified 3,3'-diindolylmethane ligand.

Katja Dankhoff1, Aamir Ahmad2, Birgit Weber1, Bernhard Biersack3, Rainer Schobert4.   

Abstract

In order to identify new active drug candidates against cancer diseases we investigated the tumor cell growth inhibition, formation of reactive oxygen species, mitochondrial membrane damage, cell cycle arrest and DNA binding activity of a new bis(triethylammonium) tris[1,1-bis(indol-3-yl)-1-(3,4-catecholate)methane]vanadate(IV) complex. It exhibited significant antiproliferative activity against various cancer cell lines, showed a stronger DNA binding than cisplatin and led to mitochondrial damage, a formation of reactive oxygen species, and a cell cycle arrest in the G2/M phase of cancer cells.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticancer drugs; DNA binding; Diindolylmethane; Reactive oxygen species; Vanadium

Mesh:

Substances:

Year:  2019        PMID: 30784705     DOI: 10.1016/j.jinorgbio.2019.02.005

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  3 in total

Review 1.  3,3'-Diindolylmethane and its derivatives: nature-inspired strategies tackling drug resistant tumors by regulation of signal transduction, transcription factors and microRNAs.

Authors:  Bernhard Biersack
Journal:  Cancer Drug Resist       Date:  2020-10-12

Review 2.  Molecular and Cellular Mechanisms of Cytotoxic Activity of Vanadium Compounds against Cancer Cells.

Authors:  Szymon Kowalski; Dariusz Wyrzykowski; Iwona Inkielewicz-Stępniak
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411

3.  Understanding the Potential In Vitro Modes of Action of Bis(β-diketonato) Oxovanadium(IV) Complexes.

Authors:  Baris Sergi; Ipek Bulut; Ying Xia; Zoë A E Waller; Yasemin Yildizhan; Ceyda Acilan; Rianne M Lord
Journal:  ChemMedChem       Date:  2021-05-26       Impact factor: 3.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.